UNSPSC 51294001: Aprepitant

This classification denotes an antiemetic agent with the molecular formula C23H21F7N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1NF15YR6UY, chemically known as 3h-1,2,4-triazol-3-one, 5-(((2r,3s)-2-((1r)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-1,2-dihydro- but generally known as aprepitant, which bears US NIH Compound Identifier 151165. European Medicines Agency schedules Aprepitant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20017.

UNSPSC 51294001 Aprepitant is a Commodity code that nominally names a specific antiemetic pharmaceutical product, but recent state and local procurement activity under this code shows little alignment with aprepitant specifically. Instead, the opportunities posted reveal a broader set of pharmaceutical and health-related product procurements spanning naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products. State and local buyers using this code tag include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances. The scope of actual buying ranges from emergency response supplies (naloxone and safe drug deactivation systems) to bulk generic pharmaceutical distribution through authorized wholesale channels, reflecting a mismatch between the code's specific product name and the category of work issuing bodies are actually marking under it.

Activity appears concentrated in the Southeast and Upper Midwest, with recent solicitations from Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) serving Minnesota and Oregon participants. Representative opportunities include Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; the Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, exploring direct-to-manufacturer prescription programs; and MMCAP's RFP S1070000015802, posted January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline and July 1, 2026 contract effective date. The Seminole County procurement requires quarterly deliveries to a community health building with drug-free workplace and E-Verify compliance; MMCAP's RFP requires cGMP and Drug Supply Chain Security Act compliance, relationships with authorized wholesalers, and a 3 percent administrative fee structure.